A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

por Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana
Publicado 2016

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer

por Frigault, Melanie M., Markovets, Aleksandra, Nuttall, Barrett, Kim, Kyoung-Mee, Park, Se Hoon, Gangolli, Esha A., Mortimer, Peter G.S., Hollingsworth, Simon J., Hong, Jung Yong, Kim, Kyung, Kim, Seung Tae, Barrett, J. Carl, Lee, Jeeyun
Publicado 2020

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

por Kim, Seung Tae, Lee, Sujin, Park, Minhwa, Park, Se Hoon, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Gangolli, Esha A., Shin, Hyeongchan, Kim, Kyoung-Mee, Hollingsworth, Simon J., Mortimer, Peter G.S., Lee, Jeeyun
Publicado 2019